Actively Recruiting
Fibroblast Growth Factor 23 and Risk of Cardiac Arrhythmias in Hemodialysis Patients
Led by Antonio Bellasi · Updated on 2025-08-05
30
Participants Needed
1
Research Sites
63 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Despite recent progress in the field of hemodialysis (HD), mortality remains unacceptably high, particularly due to cardiac arrhythmias. Recent evidence suggests that fibroblast growth factor 23 (FGF23) is implicated in the pathogenesis of cardiac arrhythmias and sudden death. However, several aspects of both the pathogenetic mechanism(s) as well as the actual association in individuals with Chronic Kidney Disease (CKD) and the effect of dialysis clearance of FGF23 need to be elucidated. The investigators aim at testing the independent association of FGF23 changes due to dialysis removal and electrocardiographic (ECG) abnormalities (namely QTc prolongation) in a well characterized sample of patients undergoing maintenance HD. The study will be developed in the Division of Nephrology, Ente Ospedaliero Cantonale.
CONDITIONS
Official Title
Fibroblast Growth Factor 23 and Risk of Cardiac Arrhythmias in Hemodialysis Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults aged over 18 years who can provide informed consent
- Currently on maintenance hemodialysis for at least 3 months
You will not qualify if you...
- History of cardiac arrhythmias at the time of study recruitment, including atrial fibrillation or pacemaker-assisted heart rhythm
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Servizio di Nefrologia, Ospedale Regionale di Lugano, Civico
Lugano, Switzerland, CH-6903
Actively Recruiting
Research Team
A
Antonio Bellasi, MD, PhD
CONTACT
D
Davide Salera, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here